Table 2

Univariate analysis to identify prognostic factors for regional control

Variable

No.

3- year RC

p value


Age (years)

0.146

≤ 60

32

84.4

> 60

18

61.9

Gender

0.093

Male

41

72.0

Female

9

100.0

Primary site

0.22

Nasopharynx

25

83.6

Non-Nasopharynx

25

72.0

T classification

0.121

1

14

68.8

2

19

84.2

3

8

100

4

9

55.6

T classification

0.05

1-3

41

82.0

4

9

55.6

N classification

0.43

1

12

91.7

2

30

71.9

3

8

75.0

N classification

0.194

1

12

91.7

2-3

38

72.7

Initial maximal lymph node size (cm)

0.022

≤ 2

28

88.0

> 2

22

63.6

RT modality

0.887

Conventional

4

75

3D-CRT

25

73.8

IMRT

21

81.0

Chemotherapy sequence

0.123

Neoadjuvant + concurrent1

21

71.4

Concurrent + adjuvant2

17

94.1

Concurrent only

12

64.3

Primary tumor response

< 0.001

Complete response

38

88.1

Partial response

10

50.0

Progressive disease

2

0.0

Primary tumor response

< 0.001

Complete response

38

88.1

Non-complete response

12

41.7

Residual maximal lymph node size (cm)

< 0.001

≤ 1.5

45

83.5

> 1.5

5

20.0

Lymph node necrosis

< 0.001

No

41

87.8

Yes

9

33.3

Follow-up PET report

0.349

Residual disease

4

50

Normal/Reactive change

27

78.1

Not available

19

78.9


RC: regional control

1. Two patients who received neoadjuvant chemotherapy only were included

2. Four patients who received additional one cycle of neoadjuvant chemotherapy were included

Jang et al. BMC Cancer 2012 12:59   doi:10.1186/1471-2407-12-59

Open Data